Literature DB >> 12223060

Airway smooth muscle: new targets for asthma pharmacotherapy.

Aili L Lazaar1.   

Abstract

Asthma, a chronic disease increasing in prevalence worldwide, is characterised by reversible airway obstruction, airway inflammation and airway smooth muscle (ASM) cell hyperplasia. The traditional view of ASM in asthma, as a regulator of bronchomotor tone, is rapidly changing. New evidence suggests that ASM cells also play an important role in the perpetuation of airway inflammation and airway remodelling. This review discusses the synthetic function of ASM cells, defined as the ability to secrete cytokines, chemokines and growth factors and express surface receptors that are important for cell adhesion and leukocyte activation. Finally, the efficacy of established asthma therapies in modifying the synthetic function of ASM cells are compared and novel targets for pharmacological intervention are discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12223060     DOI: 10.1517/14728222.6.4.447

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  3 in total

1.  Nuclear translocation of p65 NF-kappaB is sufficient for VCAM-1, but not ICAM-1, expression in TNF-stimulated smooth muscle cells: Differential requirement for PARP-1 expression and interaction.

Authors:  Mourad Zerfaoui; Yasuhiro Suzuki; Amarjit S Naura; Chetan P Hans; Charles Nichols; A Hamid Boulares
Journal:  Cell Signal       Date:  2007-10-12       Impact factor: 4.315

2.  Chloroquine Attenuates Asthma Development by Restoring Airway Smooth Muscle Cell Phenotype Via the ROS-AKT Pathway.

Authors:  Yan Ren; Xiuhua Zhong; Hongyu Wang; Zhongqi Chen; Yanan Liu; Xiaoning Zeng; Yuan Ma
Journal:  Front Pharmacol       Date:  2022-06-01       Impact factor: 5.988

3.  Simulations demonstrate a simple network to be sufficient to control branch point selection, smooth muscle and vasculature formation during lung branching morphogenesis.

Authors:  Géraldine Cellière; Denis Menshykau; Dagmar Iber
Journal:  Biol Open       Date:  2012-06-27       Impact factor: 2.422

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.